0000000000599545

AUTHOR

Tomoki Naoe

showing 3 related works from this author

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

2019

Abstract Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion–based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the …

Acute promyelocytic leukemiamedicine.medical_specialtymedicine.medical_treatmentImmunologyMEDLINETretinoinDiseaseHemorrhagic DisordersBiochemistryHemorrhagic disorderEuropean LeukemiaNetArsenic TrioxideLeukemia Promyelocytic AcutePregnancyRecurrenceHumansMedicineDisease management (health)Intensive care medicineSpecial ReportNeoadjuvant therapyAPL Differentiation SyndromeAgedbusiness.industryDisease ManagementCell BiologyHematologymedicine.diseasePractice Guidelines as TopicFemalebusinessBlood
researchProduct

Meeting Report: The 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology

2007

The International Conference on Differentiation Therapy group of clinicians and researchers has met for more than 20 years and the most recent meeting in 2005 was held in Shanghai, China ( [1][1]). This group fostered the required networks to translate these novel strategies to clinical practice, as

Clinical PracticeCancer Researchmedicine.medical_specialtyPathologyOncologyDifferentiation therapybusiness.industryFamily medicineeducationmedicineAlternative medicinebusinessCancer Research
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct